Henning Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Henning Andersen has a total of 339 co-authors. Here are the top co-authors by number of shared publications:
- Lotte Sahin Levison
Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
7 shared publications - John Vissing
Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Søren Hein Sindrup
Department of Neurology Odense University Hospital Odense Denmark
6 shared publications - Reimar Wernich Thomsen
Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
5 shared publications - Hatice Tankisi
Department of Clinical Neurophysiology, Aarhus University Hospital, Denmark
4 shared publications - Thomas Harbo
Department of Neurology, Aarhus University Hospital, Denmark
4 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 7
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials
Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of the acid α-glucosidase enzyme. In LOPD treatment, enzyme replacement therapy is delivered via intravenous infusion, typically in clinical settings. Cipaglucosidase alfa is delivered with the oral enzyme stabilizer miglustat (cipa + mig). Objectives: Evaluate the safety of cipa + mig home infusions. Design: Post hoc analysis of pooled safety data from three clinical trials in adults with LOPD (NCT02675465, NCT03729362, NCT04138277). Methods: The frequency and severity of infusion-associated reactions (IARs) during cipa + mig home and clinic administration were analyzed. Results: In total, 65/151 patients (43.0%) received ⩾1 cipa + mig home treatment. Of 9185 treatments, 2024 (22.0%) were administered at home. IAR frequency was similar for home (1.3%, 26/2024) and clinic (1.8%, 129/7161). The most frequent IAR following home infusion was pyrexia (6.2% of patients). Two patients with ⩾1 home-based treatment experienced serious IARs. Conclusion: Analyses support the safety of home cipa + mig treatment in eligible adults with LOPD.
- 31 January 2026
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 7
Open AccessSafety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials
Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of the acid α-glucosidase enzyme. In LOPD treatment, enzyme replacement therapy is delivered via intravenous infusion, typically in clinical settings. Cipaglucosidase alfa is delivered with the oral enzyme stabilizer miglustat (cipa + mig). Objectives: Evaluate the safety of cipa + mig home infusions. Design: Post hoc analysis of pooled safety data from three clinical trials in adults with LOPD (NCT02675465, NCT03729362, NCT04138277). Methods: The frequency and severity of infusion-associated reactions (IARs) during cipa + mig home and clinic administration were analyzed. Results: In total, 65/151 patients (43.0%) received ⩾1 cipa + mig home treatment. Of 9185 treatments, 2024 (22.0%) were administered at home. IAR frequency was similar for home (1.3%, 26/2024) and clinic (1.8%, 129/7161). The most frequent IAR following home infusion was pyrexia (6.2% of patients). Two patients with ⩾1 home-based treatment experienced serious IARs. Conclusion: Analyses support the safety of home cipa + mig treatment in eligible adults with LOPD.
- Open Access
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110985
High-frequency nerve ultrasound in Guillain-Barré syndrome
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110985
Open AccessHigh-frequency nerve ultrasound in Guillain-Barré syndrome
- Open Access
- 30 July 2025
- Published by Elsevier in Arthroplasty Today
- Vol. 34, 101754
Physical Function Following Megaprosthesis Surgery in the Lower Limb—A Prospective Cohort Study of 38 Patients
- 30 July 2025
- Published by Elsevier in Arthroplasty Today
- Vol. 34, 101754
Open AccessPhysical Function Following Megaprosthesis Surgery in the Lower Limb—A Prospective Cohort Study of 38 Patients
- 8 July 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (1) , e213809
Hospital-Diagnosed Traumatic Head Injury and Associated Risk of Developing ALS
Previous studies have suggested that traumatic head injury (THI) may be a risk factor of amyotrophic lateral sclerosis (ALS) development, yet the association remains unclear. We aimed to determine whether hospital-diagnosed THI is an important ALS risk factor, and we investigated the magnitude and duration of associated ALS risk. In this population-based case-control study, we used individual-level data linkage across nationwide health registers from 1980 to 2021 to identify patients with hospital-diagnosed ALS. Each patient was matched 1:10 with individuals from the general population by age, sex, and diagnostic index date. We used conditional logistic regression to examine the relative risk of ALS associated with having previous hospital-diagnosed THI. To avoid the effect of reverse causation, we investigated ALS risk within several time windows and repeated all analyses after restricting THI exposures to more than 3 years before the date of ALS diagnosis. THI was observed in 4.7% of 5,943 ALS cases vs 3.7% of 59,426 controls, with a matched odds ratio (OR) of 1.3 (95% CI 1.1-1.4). However, the risk of ALS declined considerably with increasing time since head injury, with a high OR of 4.5 (95% CI 2.8-7.3) observed within the 6 months before ALS diagnosis. If head injury was suffered 6-12 months before ALS diagnosis, the OR was 2.4 (95% CI 1.4-4.0). Restricting the analysis to THI suffered more than 3 years before ALS diagnosis, we found no association with an OR of 1.1 (95% CI 1.0-1.3). Although a strong association of ALS with THI experienced ≤1 year before ALS diagnosis was evident, our results suggest that this is due to reverse causation. When restricting the analysis to a period deemed relevant for causative events leading to ALS development, no association was observed. Consequently, we do not consider THI an important ALS risk factor. This study was limited by the inability to consider minor THIs not receiving hospital attendance. Future research should explore alternative models to unfold this possible ALS risk factor.
- 8 July 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (1) , e213809
Hospital-Diagnosed Traumatic Head Injury and Associated Risk of Developing ALS
Previous studies have suggested that traumatic head injury (THI) may be a risk factor of amyotrophic lateral sclerosis (ALS) development, yet the association remains unclear. We aimed to determine whether hospital-diagnosed THI is an important ALS risk factor, and we investigated the magnitude and duration of associated ALS risk. In this population-based case-control study, we used individual-level data linkage across nationwide health registers from 1980 to 2021 to identify patients with hospital-diagnosed ALS. Each patient was matched 1:10 with individuals from the general population by age, sex, and diagnostic index date. We used conditional logistic regression to examine the relative risk of ALS associated with having previous hospital-diagnosed THI. To avoid the effect of reverse causation, we investigated ALS risk within several time windows and repeated all analyses after restricting THI exposures to more than 3 years before the date of ALS diagnosis. THI was observed in 4.7% of 5,943 ALS cases vs 3.7% of 59,426 controls, with a matched odds ratio (OR) of 1.3 (95% CI 1.1-1.4). However, the risk of ALS declined considerably with increasing time since head injury, with a high OR of 4.5 (95% CI 2.8-7.3) observed within the 6 months before ALS diagnosis. If head injury was suffered 6-12 months before ALS diagnosis, the OR was 2.4 (95% CI 1.4-4.0). Restricting the analysis to THI suffered more than 3 years before ALS diagnosis, we found no association with an OR of 1.1 (95% CI 1.0-1.3). Although a strong association of ALS with THI experienced ≤1 year before ALS diagnosis was evident, our results suggest that this is due to reverse causation. When restricting the analysis to a period deemed relevant for causative events leading to ALS development, no association was observed. Consequently, we do not consider THI an important ALS risk factor. This study was limited by the inability to consider minor THIs not receiving hospital attendance. Future research should explore alternative models to unfold this possible ALS risk factor.
- 24 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (12) , e213745
Mortality in Myasthenia Gravis in Denmark From 1985 to 2020
Myasthenia gravis (MG) is a life-threatening disease associated with elevated mortality, primarily in the first years after diagnosis. We determined short-term (<1 year) and long-term (1-5 years) mortality for patients with MG compared with the general population. Using nationwide health registers, we identified patients with MG and matched 1:10 with the general population by age, sex, and diagnostic index date from 1985 to 2020. We calculated matched hazard ratios (HRs) using Cox regression analysis, stratified by sex, age, period, and baseline comorbidities, and performed comorbidity-adjusted analyses. Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years. Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5). Short-term mortality rose from 2015 to 2020, especially in patients aged 75 years or older (HR 2.8, 95% CI 1.8-3.6). Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population. MG mortality remains elevated, especially in the first year after diagnosis in older patients, underlining the importance of early intervention and close monitoring.
- 24 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (12) , e213745
Mortality in Myasthenia Gravis in Denmark From 1985 to 2020
Myasthenia gravis (MG) is a life-threatening disease associated with elevated mortality, primarily in the first years after diagnosis. We determined short-term (<1 year) and long-term (1-5 years) mortality for patients with MG compared with the general population. Using nationwide health registers, we identified patients with MG and matched 1:10 with the general population by age, sex, and diagnostic index date from 1985 to 2020. We calculated matched hazard ratios (HRs) using Cox regression analysis, stratified by sex, age, period, and baseline comorbidities, and performed comorbidity-adjusted analyses. Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years. Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5). Short-term mortality rose from 2015 to 2020, especially in patients aged 75 years or older (HR 2.8, 95% CI 1.8-3.6). Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population. MG mortality remains elevated, especially in the first year after diagnosis in older patients, underlining the importance of early intervention and close monitoring.
- Open Access
- 16 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70211
Societal Costs, Healthcare Utilisation and Labour Market Affiliation of Persons With Adult‐Onset Myotonic Dystrophy Type 1 (DM1)—A Register‐Based Study II
Background: Adult‐onset myotonic dystrophy type 1 (DM1) is characterised by diagnostic delay due to milder symptomatology than the congenital and juvenile forms. The multiorgan symptoms in the multiorgan nature of DM1 have negative biopsychosocial consequences. The aim was to apply national health registers to provide updated knowledge on the use and costs of healthcare services and labour market affiliation of persons with adult‐onset DM1 in Denmark.Methods: Analyses were based on a population of 949 adult persons with DM1 and 9427 controls. Median age at diagnosis was 43 years. Each person with DM1 was matched with ten reference individuals from the general Danish population without DM1. Data were retrieved from several databases: Statistics Denmark, the Danish National Patient Register, Danish National Health Service Register, the Danish National Prescription Registry and the Income register and the DREAM database.Results: During the 20‐year following diagnosis, persons with DM1 had 2.5 times more inpatient contacts, 2 times more outpatient contacts and 29.1 times more hours of home care than their controls. Persons with DM1 had a lower educational level, a higher risk of early disability pension (HR: 11.6, CI: 9.92–13.6), 68.2 weeks more unemployment and 29.2 weeks more long‐term sick leave and EUR 11,700–23,500 a lower income per year of the study. For all results, the difference between persons with DM1 and their controls was more expressed in males.Conclusions: The course of disease in adult‐onset DM1—normally considered to be mild—has a significant impact on health and living conditions.
- 16 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70211
Open AccessSocietal Costs, Healthcare Utilisation and Labour Market Affiliation of Persons With Adult‐Onset Myotonic Dystrophy Type 1 (DM1)—A Register‐Based Study II
Background: Adult‐onset myotonic dystrophy type 1 (DM1) is characterised by diagnostic delay due to milder symptomatology than the congenital and juvenile forms. The multiorgan symptoms in the multiorgan nature of DM1 have negative biopsychosocial consequences. The aim was to apply national health registers to provide updated knowledge on the use and costs of healthcare services and labour market affiliation of persons with adult‐onset DM1 in Denmark.Methods: Analyses were based on a population of 949 adult persons with DM1 and 9427 controls. Median age at diagnosis was 43 years. Each person with DM1 was matched with ten reference individuals from the general Danish population without DM1. Data were retrieved from several databases: Statistics Denmark, the Danish National Patient Register, Danish National Health Service Register, the Danish National Prescription Registry and the Income register and the DREAM database.Results: During the 20‐year following diagnosis, persons with DM1 had 2.5 times more inpatient contacts, 2 times more outpatient contacts and 29.1 times more hours of home care than their controls. Persons with DM1 had a lower educational level, a higher risk of early disability pension (HR: 11.6, CI: 9.92–13.6), 68.2 weeks more unemployment and 29.2 weeks more long‐term sick leave and EUR 11,700–23,500 a lower income per year of the study. For all results, the difference between persons with DM1 and their controls was more expressed in males.Conclusions: The course of disease in adult‐onset DM1—normally considered to be mild—has a significant impact on health and living conditions.
- Open Access
- 8 April 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (4) , e70135
Multiorgan Involvement and Mortality in Individuals With Adult‐Onset Myotonic Dystrophy (DM1)—A Danish Register‐Based Study I
Background and Purpose: Adult‐onset myotonic dystrophy type 1 (DM1) is characterized by a diagnostic delay due to milder symptoms than the infantile and juvenile forms. Despite this, there is a risk of negative biopsychosocial consequences, particularly due to the cognitive impact. Individuals with adult‐onset DM1 may receive less attention and have lower adherence to hospital follow‐ups, which increases the risk of adverse events and early death. The aim of this study was to provide knowledge on the time of diagnosis, multiorgan involvement, and mortality in a national cohort of individuals with adult‐onset DM1.Methods: Data from individuals with DM1 were extracted from the Danish National Health and administrative registers in the period 1994–2022; each individual with DM1 was paired with 10 reference individuals from the general Danish population.Results: Analyses were based on 949 individuals with DM1 and 9427 controls. The median age at diagnosis was 43 years; 40% of individuals had a parent–child relationship. Respiratory insufficiency and cataracts were the most common involvements among individuals with DM1. The average age at death was 58 years; risk of mortality was 5.87 times higher than controls (p < 0.001) and individuals with DM1 and cardiovascular disease had a higher mortality rate compared to controls (HR: 2.63, CI: 2.14–3.23, p < 0.001). The risk of mortality tended to decline in the later years of the study period.Conclusion: Despite adult‐onset DM1 often being characterized as mild, comorbidities and an excess risk of death are major concerns. This calls for attention from health professionals to improve rehabilitation and survival for this population.
- 8 April 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (4) , e70135
Open AccessMultiorgan Involvement and Mortality in Individuals With Adult‐Onset Myotonic Dystrophy (DM1)—A Danish Register‐Based Study I
Background and Purpose: Adult‐onset myotonic dystrophy type 1 (DM1) is characterized by a diagnostic delay due to milder symptoms than the infantile and juvenile forms. Despite this, there is a risk of negative biopsychosocial consequences, particularly due to the cognitive impact. Individuals with adult‐onset DM1 may receive less attention and have lower adherence to hospital follow‐ups, which increases the risk of adverse events and early death. The aim of this study was to provide knowledge on the time of diagnosis, multiorgan involvement, and mortality in a national cohort of individuals with adult‐onset DM1.Methods: Data from individuals with DM1 were extracted from the Danish National Health and administrative registers in the period 1994–2022; each individual with DM1 was paired with 10 reference individuals from the general Danish population.Results: Analyses were based on 949 individuals with DM1 and 9427 controls. The median age at diagnosis was 43 years; 40% of individuals had a parent–child relationship. Respiratory insufficiency and cataracts were the most common involvements among individuals with DM1. The average age at death was 58 years; risk of mortality was 5.87 times higher than controls (p < 0.001) and individuals with DM1 and cardiovascular disease had a higher mortality rate compared to controls (HR: 2.63, CI: 2.14–3.23, p < 0.001). The risk of mortality tended to decline in the later years of the study period.Conclusion: Despite adult‐onset DM1 often being characterized as mild, comorbidities and an excess risk of death are major concerns. This calls for attention from health professionals to improve rehabilitation and survival for this population.
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210139
Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021
Previous studies on incident myasthenia gravis (MG) have shown inconsistent results. In this study, we determined the MG incidence rates (IRs) over a 36-year period to detect potential trends in MG incidence over time and for different age groups. In this nationwide population-based study from 1985 to 2021, we identified patients aged 18 and older with a primary MG diagnosis in the Danish National Patient Registry. The patients were categorized into 3 distinct groups defined by age at onset: early-onset (≤50 years of age), late-onset (>50 and ≤65 years of age), and very late-onset (>65 years of age). MG IRs were calculated and stratified by sex and time periods in the specified age groups. To increase the validity of the MG IRs, we performed sensitivity analyses from 1995 until 2021, adding ≥2 prescriptions of pyridostigmine and/or acetylcholine receptor seropositivity. We identified 2,110 patients with MG (1,060 women), with a median age of 57.1 (interquartile range [IQR] 40.2-74.0) years for women and 63.6 (IQR 56.4-74.3) years for men. In the study period, the MG IR was 1.4 (95% CI 1.3-1.4) per 100,000 person-years, which persisted in our sensitivity analyses, with no significant differences between the sexes. Overall, 579 patients (27.4%) were classified as early-onset, 490 (23.2%) as late-onset, and 1,040 (49.3%) as very late-onset. For early-onset MG, the IR was 0.7 (95% CI 0.6-0.7) and remained stable throughout the study period. Inversely, the IRs for late-onset and very late-onset MG increased over time, with corresponding incidence rate ratios (IRRs) of 1.9 (95% CI 1.3-2.6) and 2.2 (95% CI 1.7-2.9), from the first 5 years from 1985 to 1990 until the last 6 years of the study period from 2015 to 2021. The overall IR of MG increased from 1985 to 2021, aligning with recent reports from neighboring European countries. The most significant rise occurred during the last 6 years of the study period compared with the first 5 years, with an IRR reaching 1.9 (95% CI 1.6-2.3). This increase in IRs was observed only in the late-onset and very late-onset age groups.
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210139
Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021
Previous studies on incident myasthenia gravis (MG) have shown inconsistent results. In this study, we determined the MG incidence rates (IRs) over a 36-year period to detect potential trends in MG incidence over time and for different age groups. In this nationwide population-based study from 1985 to 2021, we identified patients aged 18 and older with a primary MG diagnosis in the Danish National Patient Registry. The patients were categorized into 3 distinct groups defined by age at onset: early-onset (≤50 years of age), late-onset (>50 and ≤65 years of age), and very late-onset (>65 years of age). MG IRs were calculated and stratified by sex and time periods in the specified age groups. To increase the validity of the MG IRs, we performed sensitivity analyses from 1995 until 2021, adding ≥2 prescriptions of pyridostigmine and/or acetylcholine receptor seropositivity. We identified 2,110 patients with MG (1,060 women), with a median age of 57.1 (interquartile range [IQR] 40.2-74.0) years for women and 63.6 (IQR 56.4-74.3) years for men. In the study period, the MG IR was 1.4 (95% CI 1.3-1.4) per 100,000 person-years, which persisted in our sensitivity analyses, with no significant differences between the sexes. Overall, 579 patients (27.4%) were classified as early-onset, 490 (23.2%) as late-onset, and 1,040 (49.3%) as very late-onset. For early-onset MG, the IR was 0.7 (95% CI 0.6-0.7) and remained stable throughout the study period. Inversely, the IRs for late-onset and very late-onset MG increased over time, with corresponding incidence rate ratios (IRRs) of 1.9 (95% CI 1.3-2.6) and 2.2 (95% CI 1.7-2.9), from the first 5 years from 1985 to 1990 until the last 6 years of the study period from 2015 to 2021. The overall IR of MG increased from 1985 to 2021, aligning with recent reports from neighboring European countries. The most significant rise occurred during the last 6 years of the study period compared with the first 5 years, with an IRR reaching 1.9 (95% CI 1.6-2.3). This increase in IRs was observed only in the late-onset and very late-onset age groups.
- Open Access
- 13 December 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 320-331
Neuromuscular transmission deficits in patients with CMT and ClC‐1 inhibition in CMT animal models
Objective: Charcot–Marie Tooth (CMT) is a hereditary neuropathy characterized by muscle weakness and fatigue with no approved therapies. Preclinical studies implicate neuromuscular junction (NMJ) transmission deficits in muscle dysfunction in CMT. This study aimed to evaluate NMJ function in patients with CMT types 1 and 2, and to determine whether enhancing NMJ transmission can improve muscle function in preclinical CMT models.Methods: First, an observational study involving single fiber electromyography (SFEMG) and clinical testing in patients with CMT 1 and 2 and healthy controls (HC) was conducted. Next, preclinical studies examined muscle function, specifically nerve‐stimulated muscle force after partially inhibiting ClC‐1 chloride channels with the novel small molecule NMD670.Results: Twenty‐one CMT patients (46.4 ± 14.4 years) and 10 HC (43.3 ± 12.7 years) were enrolled. SFEMG jitter (NMJ variability) was higher [median (range)] in the CMT patients [56 μs (35; 197 μs)] vs. HC [29 μs (19; 36 μs)], (p < 0.05). Blocking (NMJ failure) was higher in the CMT patients (13.4% (0.0; 90.9%)) vs. HC (0.0% (0.0; 4.5%)), (p < 0.05). In CMT, jitter and blocking correlated inversely with muscle strength, mobility, balance, and endurance. In CMT 1A and 2D mice, NMD670 increased both peak force and contractile endurance in vivo.Interpretation: Our study suggests that NMJ dysfunction contributes to muscle dysfunction in patients with CMT 1 and 2. Furthermore, our preclinical data provide proof‐of‐mechanism for recovery of muscle function with ClC‐1 inhibition in CMT mouse models. Collectively, these findings suggest that targeting NMJ dysfunction with ClC‐1 inhibitors could enhance muscle function in CMT patients, warranting further clinical trials.
- 13 December 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 320-331
Open AccessNeuromuscular transmission deficits in patients with CMT and ClC‐1 inhibition in CMT animal models
Objective: Charcot–Marie Tooth (CMT) is a hereditary neuropathy characterized by muscle weakness and fatigue with no approved therapies. Preclinical studies implicate neuromuscular junction (NMJ) transmission deficits in muscle dysfunction in CMT. This study aimed to evaluate NMJ function in patients with CMT types 1 and 2, and to determine whether enhancing NMJ transmission can improve muscle function in preclinical CMT models.Methods: First, an observational study involving single fiber electromyography (SFEMG) and clinical testing in patients with CMT 1 and 2 and healthy controls (HC) was conducted. Next, preclinical studies examined muscle function, specifically nerve‐stimulated muscle force after partially inhibiting ClC‐1 chloride channels with the novel small molecule NMD670.Results: Twenty‐one CMT patients (46.4 ± 14.4 years) and 10 HC (43.3 ± 12.7 years) were enrolled. SFEMG jitter (NMJ variability) was higher [median (range)] in the CMT patients [56 μs (35; 197 μs)] vs. HC [29 μs (19; 36 μs)], (p < 0.05). Blocking (NMJ failure) was higher in the CMT patients (13.4% (0.0; 90.9%)) vs. HC (0.0% (0.0; 4.5%)), (p < 0.05). In CMT, jitter and blocking correlated inversely with muscle strength, mobility, balance, and endurance. In CMT 1A and 2D mice, NMD670 increased both peak force and contractile endurance in vivo.Interpretation: Our study suggests that NMJ dysfunction contributes to muscle dysfunction in patients with CMT 1 and 2. Furthermore, our preclinical data provide proof‐of‐mechanism for recovery of muscle function with ClC‐1 inhibition in CMT mouse models. Collectively, these findings suggest that targeting NMJ dysfunction with ClC‐1 inhibitors could enhance muscle function in CMT patients, warranting further clinical trials.
- Open Access
- 11 November 2024
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 29 (4) , 441-452
Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial
Background and Aims: Hyaluronidase‐facilitated subcutaneous immunoglobulin (fSCIG) consists of subcutaneous human immunoglobulin G (IgG) 10% with recombinant human hyaluronidase (rHuPH20) and can be administered at the same dose and interval as intravenous IgG (IVIG). fSCIG recently received US approval as maintenance therapy for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and European approval for adults and children with CIDP after stabilization with IVIG.Methods: ADVANCE‐CIDP 3 (NCT02955355) was an open‐label long‐term extension of the Phase 3 double‐blind randomized placebo‐controlled ADVANCE‐CIDP 1 study (NCT02549170) that examined fSCIG safety and efficacy as maintenance CIDP therapy. Primary outcomes were safety, tolerability, and immunogenicity. Efficacy was an exploratory outcome.Results: The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%). Median (range) 4‐weekly IgG dose equivalent was 64.0 (28.0–200.0) g. Mean (standard deviation) infusion duration was 135.5 (62.8) minutes. Most adverse events (AEs) were mild or moderate and self‐limiting. Of the 1406 AEs, only 48 were severe and 30 were serious. fSCIG‐related AEs (n = 798) included infusion site reactions such as pain, redness, and pruritus. Three infusions (0.1%) were reduced in rate, interrupted, or stopped due to intolerability. Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%. An anti‐rHuPH20 antibody titer ≥1:160 was detected in 14 of 84 patients (16.7%); patients who tested positive (≥1:160) had similar relapse rates versus those who tested negative (16.7% vs. 12.3%, respectively).Interpretation: ADVANCE‐CIDP 3 demonstrated favorable fSCIG long‐term safety and tolerability consistent with its established safety profile, and a low relapse rate, supporting use as maintenance CIDP treatment.
- 11 November 2024
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 29 (4) , 441-452
Open AccessLong‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial
Background and Aims: Hyaluronidase‐facilitated subcutaneous immunoglobulin (fSCIG) consists of subcutaneous human immunoglobulin G (IgG) 10% with recombinant human hyaluronidase (rHuPH20) and can be administered at the same dose and interval as intravenous IgG (IVIG). fSCIG recently received US approval as maintenance therapy for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and European approval for adults and children with CIDP after stabilization with IVIG.Methods: ADVANCE‐CIDP 3 (NCT02955355) was an open‐label long‐term extension of the Phase 3 double‐blind randomized placebo‐controlled ADVANCE‐CIDP 1 study (NCT02549170) that examined fSCIG safety and efficacy as maintenance CIDP therapy. Primary outcomes were safety, tolerability, and immunogenicity. Efficacy was an exploratory outcome.Results: The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%). Median (range) 4‐weekly IgG dose equivalent was 64.0 (28.0–200.0) g. Mean (standard deviation) infusion duration was 135.5 (62.8) minutes. Most adverse events (AEs) were mild or moderate and self‐limiting. Of the 1406 AEs, only 48 were severe and 30 were serious. fSCIG‐related AEs (n = 798) included infusion site reactions such as pain, redness, and pruritus. Three infusions (0.1%) were reduced in rate, interrupted, or stopped due to intolerability. Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%. An anti‐rHuPH20 antibody titer ≥1:160 was detected in 14 of 84 patients (16.7%); patients who tested positive (≥1:160) had similar relapse rates versus those who tested negative (16.7% vs. 12.3%, respectively).Interpretation: ADVANCE‐CIDP 3 demonstrated favorable fSCIG long‐term safety and tolerability consistent with its established safety profile, and a low relapse rate, supporting use as maintenance CIDP treatment.